These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16911080)

  • 21. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.
    Parnes C; Guillermin J; Habersang R; Nicholes P; Chawla V; Kelly T; Fishbein J; McRae P; Goessler M; Gatti A; Calcagno JA; Eki C; Harris KA; Joyave J; McFarland K; Protter P; Sullivan M; Stanford A; Lovett N; Ortiz M; Rojas S; Cyrus S; Cyrus J; Cohen S; Buchin D; Riordan L; Zuniga M; Shah R; Minard C; Quintin A; Douglas G; van Houten J; Freutner S; Chartrand S; Nowatzke P; Romero J; Rhodes T; Benoit M; Walter E; Walker L; DeBonnett L; Cross M; Free T; Martin S; Shank K; Guedes B; Atkinson LA; Halpin GJ; Rouse K; Hand I; Geiss D; Marshall JR; Burleson L; Boland J; Seybold K; Hunter V; Unfer S; Schmucker J; Gley M; Marcus M; Thompson P; Milla P; Young C; Zanni R; Zinno V; Fetter-Zarzeka A; Busey A; Sokunbi MA; Airington S; Richard N; Muraligopal V; Lewis S; Weber FT; Giordano BP; Linehan D; Roach J; Davis R; Rzepka AA; Booth T; Smeltzer D; Walsh J; Arispe E; Rowley R; Bolling C; Botts T; Haskett K; Raby D; Batiz E; Gelfand A; Farrell L; Butler S; Colby L; Schochet P; Bentler J; Hirsch D; Wilkinson L; Aaronson A; Bennett E; Wingate J; Quinn D; Komendowski K; Deckard M; Frogel M; Nerwen C; Copenhaver S; Prater M; Wolsztein J; Mackey K; Benbow M; Naranjo M; Hensley S; Hayes C; Sadeghi H; Lawson SM; McCall M; Combs K; Ledbetter J; Sarnosky K; Swafford C; Speer M; Barton WJ; Mink JW; Lemm D; Hudak M; Case E; Rowen J; Fuentes S; Pane C; Richardson L; Chavarria C; Cassino D; Ghaffari K; Carroll C; Lee H; Guclu L; Johnson C; Blum V; Boron ML; Sorrentino M; Hirsch RL; Van Veldhuisen PC; Smith C;
    Pediatr Pulmonol; 2003 Jun; 35(6):484-9. PubMed ID: 12746948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
    Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
    Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of palivizumab in preterm infants 29 to 32 weeks' gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection.
    Groothuis JR
    Eur J Clin Microbiol Infect Dis; 2003 Jul; 22(7):414-7. PubMed ID: 12827537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
    Rajah B; Sánchez PJ; Garcia-Maurino C; Leber A; Ramilo O; Mejias A
    J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
    Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
    Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
    South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season.
    Fanos V; Scarcella A; Puddu M; Gallini F; Tuminelli F; Bragetti P; Gallina MR; Quartulli L; Benincori N; Citro G; Via LD; Barera G; DI Luzio Paparatti U; Merolla R; Romano GV; Guida G; Silvestri M; Rossi GA
    J Chemother; 2009 Jun; 21(3):302-10. PubMed ID: 19567351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.
    Vogel AM; Lennon DR; Broadbent R; Byrnes CA; Grimwood K; Mildenhall L; Richardson V; Rowley S
    J Paediatr Child Health; 2002 Dec; 38(6):550-4. PubMed ID: 12410864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections].
    Scholz H
    Z Geburtshilfe Neonatol; 2000; 204(3):120-2. PubMed ID: 10909169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use of palivizumab in the prevention of syncytial virus respiratory infection].
    Vagnarelli F; Magnani C; Vancini A; Bonacini G; Iori A; Mariani S; Attanasio M; Banchini G
    Acta Biomed Ateneo Parmense; 2000; 71 Suppl 1():573-5. PubMed ID: 11424809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
    J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.
    Checchia PA; Nalysnyk L; Fernandes AW; Mahadevia PJ; Xu Y; Fahrbach K; Welliver RC
    Pediatr Crit Care Med; 2011 Sep; 12(5):580-8. PubMed ID: 21200358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short- and Long-term Pulmonary Outcome of Palivizumab in Children Born Extremely Prematurely.
    Prais D; Kaplan E; Klinger G; Mussaffi H; Mei-Zahav M; Bar-Yishay E; Stafler P; Steuer G; Sirota L; Blau H
    Chest; 2016 Mar; 149(3):801-8. PubMed ID: 26226546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Palivizumab for preterm infants. Is it worth it?
    Embleton ND; Harkensee C; Mckean MC
    Arch Dis Child Fetal Neonatal Ed; 2005 Jul; 90(4):F286-9. PubMed ID: 16036888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Chemoprophylaxis with palivizumab in Andalusia (Spain). Results of the 2000-2001 respiratory syncytial virus epidemic].
    Grupo de Hospitales Benazuza
    An Esp Pediatr; 2002 Apr; 56(4):293-7. PubMed ID: 11927095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.